Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 13/20 | 0.42 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334410 | 0.90 | SLC6A9 (0.53) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL5563352 | 0.89 | SLC6A9 (0.54) | GPR119SLC6A9 | |
| SCHEMBL5563268 | 0.89 | SLC6A9 (0.52) | GPR119SLC6A9OPRM1SLC6A5 | |
| SCHEMBL5557626 | 0.88 | SLC6A9 (0.53) | GPR119SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138300 | 0.88 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL14058697 | 0.86 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL4331180 | 0.86 | SLC6A9 (0.41) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL14057437 | 0.83 | SLC6A9 (0.48) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL15437748 | 0.78 | DDB1 (0.44) | GPR119 | |
| SCHEMBL14126822 | 0.78 | SLC6A9 (0.49) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440542-B1 | Substituted benzimidazoles, benzonthiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-2440542-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| WO-2010142402-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010142402-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | BDKRB1, BDKRB2, BRD1 | GPR119 466/4885SLC6A9 3380/4885NAMPT 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.